China’s 14th Five-Year Plan for the Pharmaceutical Industry highlights AI and quantum computing to accelerate drug development. It promotes ultra-limit manufacturing, space-based pharma, and biomanufacturing while advancing gene editing, cell therapy, and organoids. Key breakthroughs include artificial life systems, radiopharmaceuticals, and xenotransplantation organs to foster new industry growth points through interdisciplinary integration of enterprises and research institutions.